Alseres Pharmaceuticals, Inc. (ALSE)
USD 0.01
(100.0%)
USD 0.01
(100.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2013 | 7.81 Million USD | 22.0% |
| 2012 | 6.41 Million USD | -76.88% |
| 2011 | 27.72 Million USD | -17.86% |
| 2010 | 33.75 Million USD | -5.32% |
| 2009 | 35.65 Million USD | 5.95% |
| 2008 | 33.64 Million USD | 44.2% |
| 2007 | 23.33 Million USD | 191.69% |
| 2006 | 8 Million USD | 2816.24% |
| 2005 | 274.32 Thousand USD | 0.0% |
| 2004 | - USD | -100.0% |
| 2003 | 3.81 Million USD | -1.52% |
| 2002 | 3.86 Million USD | 0.0% |
| 2001 | - USD | 0.0% |
| 2000 | - USD | -100.0% |
| 1999 | 4.6 Million USD | 0.0% |
| 1998 | - USD | 0.0% |
| 1997 | - USD | -100.0% |
| 1996 | 100 Thousand USD | -95.45% |
| 1995 | 2.2 Million USD | 633.33% |
| 1994 | 300 Thousand USD | -40.0% |
| 1993 | 500 Thousand USD | -16.67% |
| 1992 | 600 Thousand USD | 50.0% |
| 1991 | 400 Thousand USD | 33.33% |
| 1990 | 300 Thousand USD | 0.0% |
| 1989 | 300 Thousand USD | 200.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2014 Q2 | 8.41 Million USD | 3.53% |
| 2014 Q1 | 8.12 Million USD | 3.95% |
| 2013 FY | 7.81 Million USD | 22.0% |
| 2013 Q2 | 6.46 Million USD | 0.78% |
| 2013 Q4 | 7.81 Million USD | 16.98% |
| 2013 Q3 | 6.68 Million USD | 3.48% |
| 2013 Q1 | 6.41 Million USD | 0.0% |
| 2012 Q2 | 28.01 Million USD | 1.03% |
| 2012 FY | 6.41 Million USD | -76.88% |
| 2012 Q1 | 27.72 Million USD | 0.0% |
| 2012 Q3 | 12.23 Million USD | -56.31% |
| 2012 Q4 | 6.41 Million USD | -47.62% |
| 2011 Q1 | 34.34 Million USD | 1.73% |
| 2011 Q4 | 27.72 Million USD | -22.11% |
| 2011 Q3 | 35.6 Million USD | 1.42% |
| 2011 FY | 27.72 Million USD | -17.86% |
| 2011 Q2 | 35.1 Million USD | 2.21% |
| 2010 Q1 | 36.62 Million USD | 2.73% |
| 2010 Q3 | 33.07 Million USD | -11.54% |
| 2010 Q4 | 33.75 Million USD | 2.06% |
| 2010 FY | 33.75 Million USD | -5.32% |
| 2010 Q2 | 37.39 Million USD | 2.08% |
| 2009 Q3 | 35.13 Million USD | 0.4% |
| 2009 Q2 | 34.99 Million USD | 0.54% |
| 2009 Q4 | 35.65 Million USD | 1.48% |
| 2009 Q1 | 34.8 Million USD | 3.43% |
| 2009 FY | 35.65 Million USD | 5.95% |
| 2008 FY | 33.64 Million USD | 44.2% |
| 2008 Q4 | 33.64 Million USD | 1.08% |
| 2008 Q3 | 33.29 Million USD | 0.14% |
| 2008 Q2 | 33.24 Million USD | 18.37% |
| 2008 Q1 | 28.08 Million USD | 20.35% |
| 2007 Q2 | 14.54 Million USD | -23.46% |
| 2007 FY | 23.33 Million USD | 191.69% |
| 2007 Q4 | 23.33 Million USD | 0.52% |
| 2007 Q3 | 23.21 Million USD | 59.63% |
| 2007 Q1 | 19 Million USD | 137.5% |
| 2006 FY | 8 Million USD | 2816.24% |
| 2006 Q4 | 8 Million USD | 300.0% |
| 2006 Q2 | - USD | -100.0% |
| 2006 Q1 | 261.33 Thousand USD | -4.74% |
| 2006 Q3 | 2 Million USD | 0.0% |
| 2005 FY | 274.32 Thousand USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 Q4 | 274.32 Thousand USD | 0.0% |
| 2004 Q4 | - USD | -100.0% |
| 2004 FY | - USD | -100.0% |
| 2004 Q1 | 3.9 Million USD | 2.4% |
| 2004 Q2 | 3.99 Million USD | 2.34% |
| 2004 Q3 | 4.08 Million USD | 2.29% |
| 2003 FY | 3.81 Million USD | -1.52% |
| 2003 Q2 | 3.87 Million USD | 7.36% |
| 2003 Q3 | 3.93 Million USD | 1.52% |
| 2003 Q4 | 3.81 Million USD | -3.21% |
| 2003 Q1 | 3.61 Million USD | -6.64% |
| 2002 Q1 | - USD | 0.0% |
| 2002 Q3 | - USD | 0.0% |
| 2002 FY | 3.86 Million USD | 0.0% |
| 2002 Q4 | 3.86 Million USD | 0.0% |
| 2002 Q2 | - USD | 0.0% |
| 2001 Q2 | - USD | 0.0% |
| 2001 Q1 | - USD | 0.0% |
| 2001 Q4 | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| 2001 Q3 | - USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| 2000 Q2 | - USD | 0.0% |
| 2000 Q1 | - USD | -100.0% |
| 2000 FY | - USD | -100.0% |
| 2000 Q4 | - USD | 0.0% |
| 1999 FY | 4.6 Million USD | 0.0% |
| 1999 Q4 | 4.6 Million USD | 6.98% |
| 1999 Q3 | 4.3 Million USD | 0.0% |
| 1999 Q2 | - USD | 0.0% |
| 1999 Q1 | - USD | 0.0% |
| 1998 FY | - USD | 0.0% |
| 1998 Q1 | - USD | 0.0% |
| 1998 Q3 | - USD | 0.0% |
| 1998 Q4 | - USD | 0.0% |
| 1998 Q2 | - USD | 0.0% |
| 1997 Q4 | - USD | 0.0% |
| 1997 FY | - USD | -100.0% |
| 1997 Q3 | - USD | 0.0% |
| 1997 Q2 | - USD | 0.0% |
| 1997 Q1 | - USD | -100.0% |
| 1996 Q4 | 100 Thousand USD | 0.0% |
| 1996 Q3 | 100 Thousand USD | 0.0% |
| 1996 Q2 | 100 Thousand USD | -50.0% |
| 1996 FY | 100 Thousand USD | -95.45% |
| 1996 Q1 | 200 Thousand USD | -90.91% |
| 1995 Q4 | 2.2 Million USD | 4.76% |
| 1995 FY | 2.2 Million USD | 633.33% |
| 1995 Q1 | 200 Thousand USD | -33.33% |
| 1995 Q2 | 1.9 Million USD | 850.0% |
| 1995 Q3 | 2.1 Million USD | 10.53% |
| 1994 FY | 300 Thousand USD | -40.0% |
| 1994 Q4 | 300 Thousand USD | 0.0% |
| 1994 Q3 | 300 Thousand USD | 0.0% |
| 1994 Q2 | 300 Thousand USD | 0.0% |
| 1994 Q1 | 300 Thousand USD | -40.0% |
| 1993 Q2 | 500 Thousand USD | -16.67% |
| 1993 FY | 500 Thousand USD | -16.67% |
| 1993 Q1 | 600 Thousand USD | 0.0% |
| 1993 Q3 | 400 Thousand USD | -20.0% |
| 1993 Q4 | 500 Thousand USD | 25.0% |
| 1992 Q1 | 300 Thousand USD | -25.0% |
| 1992 Q3 | 600 Thousand USD | -14.29% |
| 1992 Q4 | 600 Thousand USD | 0.0% |
| 1992 FY | 600 Thousand USD | 50.0% |
| 1992 Q2 | 700 Thousand USD | 133.33% |
| 1991 Q1 | 300 Thousand USD | 0.0% |
| 1991 Q4 | 400 Thousand USD | 0.0% |
| 1991 FY | 400 Thousand USD | 33.33% |
| 1991 Q3 | 400 Thousand USD | 0.0% |
| 1990 Q4 | 300 Thousand USD | 0.0% |
| 1990 FY | 300 Thousand USD | 0.0% |
| 1989 FY | 300 Thousand USD | 200.0% |
| 1989 Q4 | 300 Thousand USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 81.021% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | -89.715% |
| SQZ Biotechnologies Company | 27.47 Million USD | 71.534% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 81.97% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 73.73% |
| Mesoblast Limited | 118.7 Million USD | 93.412% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -724.655% |
| Genus plc | 233.1 Million USD | 96.645% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | -166.857% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -482.022% |
| Marizyme, Inc. | 18.71 Million USD | 58.221% |
| ContraFect Corporation | 2.88 Million USD | -171.432% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -942.661% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -5671.742% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -440.68% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -236.204% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | -38.202% |
| MultiCell Technologies, Inc. | 202.58 USD | -3860083.631% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 86.397% |
| EV Biologics, Inc. | 1.49 Million USD | -423.161% |
| Q BioMed Inc. | 4.1 Million USD | -90.268% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 76.375% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -1141.112% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -536.617% |
| Biomind Labs Inc. | 735.54 Thousand USD | -963.156% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 95.441% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 39.833% |
| Skye Bioscience, Inc. | 4.61 Million USD | -69.437% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -780.563% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -5425.771% |
| Arch Therapeutics, Inc. | 5.87 Million USD | -33.194% |
| IMV Inc. | 28.88 Million USD | 72.926% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -30305.381% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -246.264% |
| GB Sciences, Inc. | 1.75 Million USD | -344.491% |
| Alpha Cognition Inc. | 1.22 Million USD | -540.785% |
| HST Global, Inc. | 98.31 Thousand USD | -7853.661% |
| CSL Limited | 12.18 Billion USD | 99.936% |
| Halberd Corporation | 150 Thousand USD | -5113.307% |
| Enzolytics Inc. | 996.33 Thousand USD | -684.87% |
| Resverlogix Corp. | 6.49 Million USD | -20.474% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | -1537.688% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -2959.548% |
| argenx SE | 20 Million USD | 60.9% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 82.836% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -188.698% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -76378.826% |
| Genscript Biotech Corporation | 417.73 Million USD | 98.128% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -3797.974% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -226.141% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -3310.496% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 88.439% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | -158.409% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -2073.962% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 61.531% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -5160.511% |
| BioStem Technologies, Inc. | 4.71 Million USD | -65.979% |
| ONE Bio Corp. | 19.71 Million USD | 60.335% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -3025.708% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -3044.082% |
| Agentix Corp. | 50 Thousand USD | -15539.92% |
| LadRx Corporation | 33.6 Thousand USD | -23169.535% |
| Cell Source, Inc. | 9.25 Million USD | 15.498% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -934.107% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -934.107% |
| NovAccess Global Inc. | 2.19 Million USD | -255.472% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -10.564% |
| Itoco Inc. | 228.37 Thousand USD | -3324.145% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -3606.581% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | -56.933% |
| Kadimastem Ltd | 891.22 Thousand USD | -777.438% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -1845.995% |
| CytoDyn Inc. | 30.07 Million USD | 73.999% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -1514.747% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -2122.546% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -6283.641% |
| Rebus Holdings, Inc. | 310 Thousand USD | -2422.568% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | -65.142% |
| International Stem Cell Corporation | 4.17 Million USD | -87.17% |
| Bioxytran, Inc. | 1.92 Million USD | -306.232% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -12429.377% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -258.566% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 5.965% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 8.911% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -402.736% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -2817.896% |
| Neutra Corp. | 54.15 Thousand USD | -14339.693% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -327.32% |
| PureTech Health plc | 25.51 Million USD | 69.348% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -538.768% |
| IXICO plc | 472.02 Thousand USD | -1556.69% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 49.552% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 87.44% |
| CSL Limited | 12.18 Billion USD | 99.936% |
| Cellectis S.A. | 92.77 Million USD | 91.571% |